Sarepta Therapeutics, Inc. $SRPT Shares Sold by BNP Paribas Financial Markets

BNP Paribas Financial Markets trimmed its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 59.1% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 727,786 shares of the biotechnology company’s stock after selling 1,053,562 shares during the period. BNP Paribas Financial Markets owned 0.69% of Sarepta Therapeutics worth $15,662,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of SRPT. Yousif Capital Management LLC boosted its stake in Sarepta Therapeutics by 1.9% in the fourth quarter. Yousif Capital Management LLC now owns 25,704 shares of the biotechnology company’s stock valued at $541,000 after acquiring an additional 481 shares during the period. Arizona State Retirement System boosted its position in shares of Sarepta Therapeutics by 2.8% during the third quarter. Arizona State Retirement System now owns 26,165 shares of the biotechnology company’s stock worth $504,000 after buying an additional 717 shares during the period. Sound View Wealth Advisors Group LLC boosted its position in shares of Sarepta Therapeutics by 6.1% during the third quarter. Sound View Wealth Advisors Group LLC now owns 12,695 shares of the biotechnology company’s stock worth $245,000 after buying an additional 728 shares during the period. Thrivent Financial for Lutherans boosted its position in shares of Sarepta Therapeutics by 3.3% during the second quarter. Thrivent Financial for Lutherans now owns 23,140 shares of the biotechnology company’s stock worth $396,000 after buying an additional 744 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Sarepta Therapeutics by 1.8% during the third quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,208 shares of the biotechnology company’s stock worth $829,000 after buying an additional 758 shares during the period. 86.68% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other Sarepta Therapeutics news, Director Stephen Mayo sold 7,239 shares of the company’s stock in a transaction on Thursday, March 12th. The stock was sold at an average price of $17.02, for a total value of $123,207.78. Following the transaction, the director owned 1,765 shares of the company’s stock, valued at approximately $30,040.30. This represents a 80.40% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 6.90% of the company’s stock.

Sarepta Therapeutics Price Performance

Shares of NASDAQ:SRPT opened at $15.75 on Friday. Sarepta Therapeutics, Inc. has a 12 month low of $10.41 and a 12 month high of $43.92. The stock has a market cap of $1.66 billion, a price-to-earnings ratio of -16.41, a PEG ratio of 0.17 and a beta of 0.21. The stock’s 50 day moving average price is $19.81 and its 200 day moving average price is $19.81. The company has a debt-to-equity ratio of 0.56, a current ratio of 4.63 and a quick ratio of 2.62.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $3.16 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.98 by $2.18. The company had revenue of $730.80 million for the quarter, compared to analysts’ expectations of $474.16 million. Sarepta Therapeutics had a positive return on equity of 7.56% and a negative net margin of 2.94%.The firm’s revenue was down 1.9% on a year-over-year basis. During the same quarter in the prior year, the company earned ($3.42) earnings per share. Equities research analysts anticipate that Sarepta Therapeutics, Inc. will post 3.99 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the company. Royal Bank Of Canada boosted their price objective on Sarepta Therapeutics from $18.00 to $19.00 and gave the stock a “sector perform” rating in a research report on Tuesday, April 7th. Mizuho boosted their price objective on Sarepta Therapeutics from $26.00 to $31.00 and gave the stock an “outperform” rating in a research report on Thursday, March 12th. Weiss Ratings downgraded Sarepta Therapeutics from a “sell (d+)” rating to a “sell (d)” rating in a research report on Tuesday, May 26th. Citigroup boosted their price objective on Sarepta Therapeutics from $9.00 to $13.00 and gave the stock a “sell” rating in a research report on Thursday, March 26th. Finally, Wall Street Zen upgraded Sarepta Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, February 28th. Eight analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and six have issued a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $24.77.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.